From: [

Sent: 26 June 2008 16:28 To: Natalie Bemrose

Subject: RE: healthcare professionals statement - Lenalidomide for multiple

myeloma in people who have received at least one prior therapy RCN

Importance: High

Dear Natalie


Nurses working in this area of health have considered the request to submit professional statement regarding the use of Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy.

There is no additional information to submit at this stage of the technology appraisal on behalf of the Royal College of Nursing.

On behalf of the RCN, we look forward to contributing in the next stage of the appraisal.

Thank you for the invitation. Please acknowledge receipt.

Regards



Tel: Fax:

The Professional Nursing Department works with RCN members and other stakeholders to develop excellence in nursing practice, influence policy and promote the science and art of nursing.

------

-----

http://www.rcn.org.uk

This email is confidential and intended solely for the use of the individual to whom it is addressed. Any views or opinions presented are solely those of the author and do not necessarily represent those of the Royal College of Nursing or any of its affiliates.

If you are not the intended recipient be advised that you have received this email in error and that any use, dissemination, forwarding, printing or copying of this email is strictly prohibited. If you have received this email in error please return it to the sender immediately. The contents of this message may be legally privileged.

Royal College of Nursing of the United Kingdom 20 Cavendish Square London W1G ORN Registered Charity Number: 276435

Tel: +44 (0) 845 456 3996

Fax: +44 (0) 20 7647 3436

Delivered via MessageLabs